Incyte Corp. (INCY) News
Filter INCY News Items
INCY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INCY News Highlights
- For INCY, its 30 day story count is now at 6.
- Over the past 15 days, the trend for INCY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, TOP and ASH are the most mentioned tickers in articles about INCY.
Latest INCY News From Around the Web
Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.
12 Most Promising Gene Editing Stocks According to Hedge FundsIn this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […] |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
The 3 Most Undervalued Biotech Stocks to Buy in DecemberBiotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. |
Incyte Stock Is the S&P 500’s Top Performer. Here’s Why It’s Surging.Shares of biopharmaceutical company Incyte were on track Tuesday for their best trading session in more than six years. The stock rose 8.6% to $61.97 on Tuesday, putting Incyte shares on pace for their largest increase since Aug. 30, 2017, when they gained 11%, according to Dow Jones Market Data. It was the top performer in the on Tuesday. |
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host DiseaseWILMINGTON, Del. & WALTHAM, Mass., December 10, 2023--Incyte and Syndax Present Additional Data from AGAVE-201 Trial at ASH Plenary Showing Axatilimab Efficacy Including Durable Responses in Chronic GVHD |
Incyte's Bullish Outlook: A Surprising Strength You Shouldn't OverlookThe company is a leader in the global myelofibrosis treatment market |
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD DrugMesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%. |